Mepro Pharmaceuticals Private Limited

Mepro Pharmaceuticals Private Limited, established on August 31, 1982, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24231GJ1982PTC005451. As of March 2026, Mepro's authorized share capital stands at ₹54 million, with a paid-up capital of ₹53.46 million. The company specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, across various therapeutic categories. Mepro's product portfolio encompasses 11 products spanning six therapeutic areas, with a significant focus on Antimalarial & Antiparasitic, Antifungals, and Cardiovascular segments. The company's total export value amounts to $17.5 million USD, distributed across 774 shipments. Notably, Mepro holds a dominant position in the Albendazole market, commanding a 6.8% share.

Mepro Pharmaceuticals operates four state-of-the-art manufacturing facilities located in different cities across India. These facilities collectively cover a constructed area of 300,000 square feet, enabling the production of a diverse range of pharmaceutical products. The manufacturing plants are equipped with advanced technology and precision-driven processes to ensure adherence to stringent quality standards. The company's commitment to quality is evident from its approvals by regulatory bodies such as the UK's MHRA and other PIC/S nations.

Mepro Pharmaceuticals is led by a team of experienced directors:

• Vijay Chhabildas Shah
• Suresh Chhabildas Shah
• Rajesh Sumanlal Shah
• Bharatkumar Chabildas Shah
• Prakash Navinchandra Shah

These directors have been instrumental in steering the company towards sustained growth and innovation in the pharmaceutical sector.

Mepro Pharmaceuticals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has secured approvals from the UK's MHRA and other PIC/S nations, reflecting its compliance with international quality standards. Mepro has also been a partner of choice for several United Nations organizations, supplying healthcare products to regions such as the West Bank, Gaza, Lebanon, Jordan, and Syria.

Mepro Pharmaceuticals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to addressing neglected tropical diseases is evident through its collaboration with global non-profit organizations to manufacture and supply treatments for conditions like Soil Transmitted Helminths (STH). Through these partnerships, Mepro reaches approximately 42 million children annually, contributing to the global effort in eradicating such diseases.

Mepro Pharmaceuticals demonstrates a diversified geographic strategy by exporting to over 40 countries, including both regulated and emerging markets. This broad market presence mitigates concentration risk and positions the company to leverage growth opportunities across different regions. The strategic direction focuses on expanding into new markets while strengthening its position in existing ones, ensuring a balanced and sustainable growth trajectory.

Mepro Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), indicating its commitment to meeting U.S. regulatory standards. The company has filed Abbreviated New Drug Applications (ANDAs) for various products, seeking approval for marketing in the U.S. market. Mepro's facilities have undergone FDA inspections, reflecting the company's adherence to Good Manufacturing Practices (GMP). The company has also filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its products.

Mepro Pharmaceuticals has achieved World Health Organization (WHO) prequalification for certain products, facilitating access to international markets and enhancing the company's credibility in the global pharmaceutical industry. The company's manufacturing facilities hold European Union Good Manufacturing Practice (EU GMP) certificates, demonstrating compliance with EU standards for pharmaceutical manufacturing. Additionally, Mepro's facilities are recognized by the European Directorate for the Quality of Medicines & HealthCare (EDQM), further validating the quality of its manufacturing processes.

In India, Mepro Pharmaceuticals holds manufacturing licenses issued by the Central Drugs Standard Control Organisation (CDSCO), authorizing the production of pharmaceutical products for domestic and export markets. The company has obtained approvals from state drug controllers, ensuring compliance with regional regulatory requirements. Mepro has also secured export No Objection Certificates (NOCs), facilitating the export of its products to various international markets.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Mepro Pharmaceuticals by regulatory authorities. This absence suggests that the company maintains a strong compliance record with regulatory agencies.

Mepro Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly disclosed, Mepro's focus on niche and technically complex pharmaceutical products positions it uniquely in the market. The company's strategic partnerships, including collaborations with United Nations organizations, further enhance its competitive edge. Mepro's commitment to quality and regulatory compliance distinguishes it from competitors, enabling the company to secure and maintain a strong market presence.

Mepro Pharmaceuticals' key differentiators include its extensive experience of over three decades in the pharmaceutical industry, a diverse product portfolio spanning multiple therapeutic categories, and a strong emphasis on quality and regulatory compliance. The company's state-of-the-art manufacturing facilities and dedicated research and development capabilities enable it to deliver innovative and high-quality pharmaceutical products. Mepro's strategic focus on addressing neglected tropical diseases and its partnerships with global organizations underscore its commitment to global health initiatives.

Mepro Pharmaceuticals' current strategic direction centers on the development and manufacturing of generic pharmaceutical products, with a particular emphasis on complex generics and niche formulations. The company's future outlook includes expanding its product offerings, enhancing research and development capabilities, and strengthening its presence in both regulated and emerging markets. Mepro aims to leverage its manufacturing expertise and regulatory approvals to drive growth and contribute to global healthcare solutions.

Mepro Pharmaceuticals has a commendable track record in pharmaceutical manufacturing, characterized by consistent export volumes and adherence to international quality standards. The company's reliability is evidenced by its partnerships with over 50 clients across more than 40 countries, and its ability to meet the stringent requirements of regulatory bodies such as the UK's MHRA and other PIC/S nations. Mepro's commitment to quality and compliance positions it as a dependable supplier in the global pharmaceutical market.

Importers should verify the following certifications when considering Mepro Pharmaceuticals as a supplier:

• FDA Facility Registration: Confirm the registration status of Mepro's manufacturing facilities with the U.S. Food and Drug Administration.

• WHO Prequalification: Verify the WHO prequalification status of Mepro's products to ensure compliance with international quality standards.

• EU GMP Certification: Check the validity of Mepro's European Union Good Manufacturing Practice certificates.

• EDQM Status: Ensure that Mepro's facilities are recognized by the European Directorate for the Quality of Medicines & HealthCare.

These certifications can typically be verified through the respective regulatory bodies' official websites or by contacting Mepro Pharmaceuticals directly.

When conducting due diligence on Mepro Pharmaceuticals, consider the following steps:

• Verify Regulatory Approvals: Confirm the validity of Mepro's certifications and approvals from relevant regulatory authorities.

• Assess Financial Health: Review the company's financial statements to evaluate its financial stability and growth trajectory.

• Evaluate Manufacturing Capabilities: Inspect Mepro's manufacturing facilities to ensure they meet required quality and compliance standards.

• Review Product Portfolio: Analyze the range and quality of products offered by Mepro to assess alignment with your requirements.

• Check References and Partnerships: Seek references from existing clients and review Mepro's partnerships with global organizations to gauge reliability and reputation.

Be vigilant for any discrepancies in certifications, financial irregularities, or non-compliance issues during the due diligence process.